DCF Advisers LLC Acquires New Holdings in AnaptysBio, Inc. $ANAB

DCF Advisers LLC bought a new stake in AnaptysBio, Inc. (NASDAQ:ANAB) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 9,114 shares of the biotechnology company’s stock, valued at approximately $615,000.

Several other hedge funds also recently bought and sold shares of the company. Tema ETFs LLC boosted its position in shares of AnaptysBio by 0.6% during the second quarter. Tema ETFs LLC now owns 31,270 shares of the biotechnology company’s stock worth $2,111,000 after purchasing an additional 201 shares in the last quarter. Los Angeles Capital Management LLC increased its position in shares of AnaptysBio by 1.5% in the 4th quarter. Los Angeles Capital Management LLC now owns 15,101 shares of the biotechnology company’s stock valued at $732,000 after buying an additional 225 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of AnaptysBio by 24.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 263 shares in the last quarter. Larson Financial Group LLC raised its stake in AnaptysBio by 21.2% during the 4th quarter. Larson Financial Group LLC now owns 1,624 shares of the biotechnology company’s stock worth $79,000 after buying an additional 284 shares during the period. Finally, Susquehanna Portfolio Strategies LLC raised its stake in AnaptysBio by 1.4% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 35,948 shares of the biotechnology company’s stock worth $1,743,000 after buying an additional 500 shares during the period.

AnaptysBio Trading Up 0.5%

Shares of NASDAQ ANAB opened at $59.26 on Thursday. The firm has a market cap of $1.75 billion, a PE ratio of -54.87 and a beta of 0.72. AnaptysBio, Inc. has a 1-year low of $11.40 and a 1-year high of $72.36. The company has a fifty day moving average price of $58.48 and a 200 day moving average price of $58.71.

Analyst Upgrades and Downgrades

ANAB has been the subject of a number of research analyst reports. HC Wainwright began coverage on AnaptysBio in a research note on Wednesday, June 10th. They issued a “buy” rating and a $95.00 target price for the company. Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Piper Sandler cut their price objective on AnaptysBio from $95.00 to $93.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. UBS Group boosted their price objective on AnaptysBio from $60.00 to $76.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Finally, Barclays increased their target price on AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.00.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.